Jan Cools
jancools.bsky.social
Jan Cools
@jancools.bsky.social
Leukemia researcher VIB-KULeuven, Editor-in-chief of HemaSphere
Reposted by Jan Cools
Explore the latest research lurking in our October issue… if you dare! 🎃👻🧟‍♀️http://bit.ly/4haMwh3
October 31, 2025 at 1:44 PM
Looking forward to this exciting meeting and to represent @hemasphere-journal.bsky.social in this session!
We are excited to announce our new #NDLR2026 Meet-the-Editor session, with Editors-in-Chief, Prof Andrew Roberts, @bloodjournals.hematology.org and Prof @jancools.bsky.social, @hemasphere-journal.bsky.social who will share their invaluable insights on #publishing in high-impact #hematology journals.
September 18, 2025 at 6:14 AM
Reposted by Jan Cools
August 3, 2025 at 8:02 AM
Great mix of art & science at the Art Science Museum in Singapore.
August 5, 2025 at 6:00 PM
Reposted by Jan Cools
In this study the authors show how cancer associated fibroblasts and their spatial architecture in the tumor microenvironment impact survival in patients with cHL. 

Read more about it here 👉https://bit.ly/4mdhPK6
June 30, 2025 at 12:02 PM
Exciting to share the new impact factor of @hemasphere-journal.bsky.social, the #openaccess journal of the European Hematology Association (EHA).
The 2024 Journal Impact Factor is 14.6 - ranking as number 5 of 99 hematology journals (Source: Journal Citations Reports, Clarivate).
June 18, 2025 at 6:07 AM
Reposted by Jan Cools
🚨Today! @ 15:45, MiCo room CORAL 6 
We warmly invite you to the HemaSphere Scientific Session where we will dive into 3 of our exciting + cutting-edge biology publications. Hope to see you there!
🕰️: 15:45 - 16:45
📍: Room CORAL 6, #EHA2025
🎤: https://bit.ly/4koLwXk
June 14, 2025 at 10:02 AM
Thank you EHA, for honoring me with the Education and Mentoring Award. Thank you Peter Marynen and Gary Gilliland for being such inspiring mentors to me! Thank you to all my trainees, all current and past members of my research group. #EHA2025 @hemasphere-journal.bsky.social
June 14, 2025 at 8:40 AM
Reposted by Jan Cools
Heading to #EHA2025 in Milan in 1.5(ish) weeks? HemaSphere has 2 exciting sessions on the program!
📌Peer Review Workshop: Fri 13 June, 13:30 - 15:00
💡Learn + master the peer review role/process
📌HemaSphere Scientific Session: Sat 14 June, 15:45 - 16:45
💡Dive into 3 of our cutting-edge biology papers
May 29, 2025 at 8:03 AM
Reposted by Jan Cools
This study examines the frequency of recurring gene mutations and their interplay with well-known biomarkers in female and male patients, between 18-80 years, with ref/rel DLBCL compared to patients with CR to identify biological risk factors associated with treatment response👉https://bit.ly/4ihynhR
April 11, 2025 at 8:31 AM
Reposted by Jan Cools
If you are interested in learning about #PDX models in in vivo drug testing, take the time to listen to the following @hemasphere-journal.bsky.social podcast featuring Prof Richard Lock. 👇
Prof. Richard Lock featured in HemaSphere podcast discussing his internationally recognised program using PDX models in preclinical testing, to study leukaemia biology and test new treatments in a highly personalised way.
ccia.support/RLpod
February 17, 2025 at 11:39 PM
Happy to share our new insights in the variant mutations driving high hyperdiploid acute lymphoblastic #leukemia - always new discoveries when you go to the #single-cell level… @hemasphere-journal.bsky.social

onlinelibrary.wiley.com/doi/full/10....
Single‐cell DNA and surface protein characterization of high hyperdiploid acute lymphoblastic leukemia at diagnosis and during treatment
High hyperdiploid (HeH) B-cell acute lymphoblastic leukemia (B-ALL) is the most prevalent subtype of childhood ALL. This leukemia is characterized by trisomies and tetrasomies of specific chromosomes...
onlinelibrary.wiley.com
February 19, 2025 at 8:57 AM
Reposted by Jan Cools
This study quantified Bcl-2 family protein expression in newly diagnosed MM patients. High levels of Bad and Puma proteins were linked to longer OS. Bcl-2 protein ratios predicting venetoclax sensitivity distinguished patients with shorter progression times 👉https://bit.ly/4fUpV6c
January 31, 2025 at 9:30 AM
Reposted by Jan Cools
We're proud to be fully open access - from day one, in fact.
Open Access makes your research free for anyone to read, use, and build on—boosting innovation and expanding reach. 🚀

👉 Check out our infographic for a quick guide on how #OpenAccess can amplify your work!
January 29, 2025 at 9:20 PM
On my way to Prague for their national hematology meeting, with my ‘retro’ EHA bag… this must be very old considering the logo…but still very useful 😊
January 22, 2025 at 7:18 PM
Reposted by Jan Cools
📢 Authors evaluated the efficacy JPX-0700 and JPX-0750 as dual STAT3/5 inhibitors, reducing leukemic cell growth in AML/NKCL models. These compounds target STAT3/5 signaling, inducing cell death and growth arrest and exhibit synergistic effects w/ approved chemotherapeutics👉https://bit.ly/42oMtJp
January 13, 2025 at 9:30 AM
Genetics is amazing 😊
December 31, 2024 at 4:18 PM
Reposted by Jan Cools
2024 has been a successful year for HemaSphere Journal!
 800+ manuscript submissions
 increasing impact in the field
 insightful graphical abstracts
 another podcast season
 ...and of course, excellent research!

We extend a warm thank you to all authors, reviewers & readers ❤️
December 31, 2024 at 9:01 AM
Reposted by Jan Cools
📖HemaSphere's December issue is now complete 👉https://bit.ly/HS_Dec2024 and as always, is 100% #OpenAccess. Please enjoy reading and feel free to share with your networks.
December 28, 2024 at 9:09 AM
Reposted by Jan Cools
Microbes support normal blood production! Authors in this recently published article report on the microbes and microbial metabolites missing from pediatric patients with antibiotic-associated neutropenia. @TheKingLab 👉https://bit.ly/4fUXyWe
December 24, 2024 at 9:02 AM
Reposted by Jan Cools
Save the date for ISEH 2025! View travel details and Annual Scientific Meeting Speakers here: www.iseh.org/page/iseh2025
December 20, 2024 at 4:38 PM
Reposted by Jan Cools
This pop-based study examines COD in 20K+ CLL pts in the Netherlands from 1996-2020. This analysis shows a noticeable ⬇️ in CLL-attributed deaths & other causes yet as CLL is registered as the most prevalent COD this emphasizes the relevance of CLL-centric clinical strategies👉https://bit.ly/4iqC859
December 16, 2024 at 9:01 AM
Very proud that my lab won the second prize of the dance competition at our VIB Center for Cancer Biology party last night 🎉🤩🥂
December 14, 2024 at 2:00 PM
Discover the podcast series of @hemasphere-journal.bsky.social
Dr C de Bock hosts Dr Mercher & Dr Fagnan on their paper highlighting ETO2 activated gene transcription & how this affects erythroleukemia, tracing the journey from PhD project, findings & what may lie beyond. Find this episode on our website https://bit.ly/4cz0Tbr & all major podcast platforms.
December 13, 2024 at 12:42 PM